KATHERINE COLLINS: Open Payments
NPI 1548802523 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,519 in 113 payments from 34 companies in 2025. Trend: 2023 $1,556 · 2024 $1,043 · 2025 $2,519
Food & beverage: $2,324Education: $195
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 15 | $352 |
| ABBVIE INC. | 13 | $303 |
| Merck Sharp & Dohme LLC | 14 | $245 |
| PFIZER INC. | 7 | $131 |
| GlaxoSmithKline, LLC. | 5 | $109 |
| Myriad Genetic Laboratories, Inc. | 1 | $105 |
| Incyte Corporation | 6 | $103 |
| Novartis Pharmaceuticals Corporation | 5 | $102 |
| SEAGEN INC. | 1 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $88 |
Products named: KEYTRUDA, RYBREVANT, VENCLEXTA, ERLEADA, MYRISK, CARVYKTI, IMBRUVICA, EPKINLY.
Industry payments across MO — which companies pay providers there.
